ATACAND®（candesartan cilexetil）.pptVIP

Regulatory (CR) ATACAND?(candesartan cilexetil) Cardiovascular and Renal DrugsAdvisory Committee Bethesda, Maryland July 18, 2002 ATACAND? Introduction and Regulatory Overview Cindy Lancaster, MS, MBA, JD Director, Regulatory Affairs AstraZeneca Agenda for Presentation Regulatory Overview Cindy Lancaster, MS, MBA, JD Director, Regulatory Affairs AstraZeneca Comparison of Vasilios Papademetriou, MD, Antihypertensive Efficacy DSc, FACCof Candesartan Cilexetil Professor of Medicineand Losartan Georgetown University Epidemiologic and Clinical William B. Kannel, MD, FACCSignificance